NasdaqGS - Nasdaq Real Time Price • USD
Grifols, S.A. (GRFS)
As of 12:09 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 6 | 5 |
| Avg. Estimate | 0.16 | 0.23 | 0.86 | 1.17 |
| Low Estimate | 0.16 | 0.23 | 0.75 | 0.95 |
| High Estimate | 0.16 | 0.23 | 0.95 | 1.32 |
| Year Ago EPS | 0.04 | 0.15 | 0.39 | 0.86 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 2 | 7 | 6 |
| Avg. Estimate | 1.78B | 4.7B | 7.48B | 8.01B |
| Low Estimate | 1.78B | 1.92B | 7.13B | 7.68B |
| High Estimate | 1.78B | 7.47B | 7.65B | 8.24B |
| Year Ago Sales | 1.7B | 1.81B | 7.03B | 7.48B |
| Sales Growth (year/est) | 4.60% | 159.50% | 6.40% | 7.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.22 | 0.18 | 0.24 | 0.24 |
| EPS Actual | 0.04 | 0.15 | 0.12 | 0.15 |
| Difference | -0.18 | -0.03 | -0.12 | -0.09 |
| Surprise % | -81.80% | -16.70% | -50.00% | -37.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.16 | 0.23 | 0.86 | 1.17 |
| 7 Days Ago | 0.16 | 0.23 | 0.86 | 1.18 |
| 30 Days Ago | 0.16 | 0.23 | 0.87 | 1.24 |
| 60 Days Ago | 0 | 0 | 1 | 1.34 |
| 90 Days Ago | 0 | 0 | 1.02 | 1.36 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GRFS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 300.00% | -- | -- | 0.80% |
| Next Qtr. | 53.30% | -- | -- | 9.60% |
| Current Year | 120.50% | -- | -- | 4.50% |
| Next Year | 36.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 34.57% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -20.29% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Downgrade | Deutsche Bank: Hold to Sell | 3/12/2024 |
| Maintains | JP Morgan: Neutral to Neutral | 12/5/2023 |
| Downgrade | Deutsche Bank: Buy to Hold | 11/5/2021 |
| Upgrade | Credit Suisse: Neutral to Outperform | 3/23/2021 |
| Upgrade | HSBC: Hold to Buy | 3/11/2021 |
| Upgrade | Santander: Hold to Buy | 10/28/2019 |
Related Tickers
ALPMY Astellas Pharma Inc.
9.50
+0.32%
SNY Sanofi
46.43
+2.28%
NVS Novartis AG
94.03
+1.58%
BAYRY Bayer Aktiengesellschaft
7.07
+0.41%
OGN Organon & Co.
17.74
-0.70%
BIIB Biogen Inc.
191.05
+0.28%
AZN AstraZeneca PLC
68.46
+0.15%
BAYN.DE Bayer Aktiengesellschaft
26.33
+0.32%
RHHBY Roche Holding AG
30.37
+1.05%
GSK GSK plc
39.63
+0.92%